Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. insulclock

INSULCLOCK

Empowered control of drugs’ dosage in chronic diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 INSULCLOCK project word cloud

Explore the words cloud of the INSULCLOCK project. It provides you a very rough idea of what is the project "INSULCLOCK" about.

cagr    25    inculclock    complications    team    reliability    mobile    fails    universal    380    additionally    insurance    total    diabetes    leads    created    market    9    patients    pool    technologies    2013    months    alliances    million    reusable    pharmaceutical    advantage    solution    last    health    serious    daily    companies    business    space    integration    demand    possibilities    international    moment    launch    barriers    definition    assistance    disease    patient    really    thanks    2025    data    full    care    injection    automatically    injected    injections    death    painful    pen    assuring    self    create    48m    electronic    vascular    insulin    dynamics    living    risk    nerve    caregivers    billion    diabetics    records    opportunity    budget    cloud    interfering    detected    15    security    insulclock    volume    pens    totaled    treatment    global    critical    uncontested    affection    stores    plan    wearable    privacy    smart   

Project "INSULCLOCK" data sheet

The following table provides information about the project.

Coordinator		 INSULCLOUD 

Organization address
address: JULIO PALACIOS, 29 13 Esc.A
city: MADRID
postcode: 28029
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website https://insulclock.com/en/
 Total cost 1˙482˙087 €
 EC max contribution 1˙037˙461 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSULCLOUD ES (MADRID) coordinator 1˙037˙461.00

Map

 Project objective

INSULCLOCK addresses the opportunity of providing a new product Within the growing market for diabetes care, a very serious and painful disease with an expected global patient pool of 380 million by 2025. More specifically, INSULCLOCK approaches the insulin pens market which totaled above 8 billion € in 2013, with a 9% CAGR for the next years. More than 25% of diabetics depend on insulin injections daily, and it is estimated that 2/3 of insulin volume is injected via injection pens. If treatment fails, there is high risk of complications related to vascular and nerve affection and even death. The goal of our project is to launch market uptake of INCULCLOCK, a solution to really help diabetics and their caregivers in self-managing their disease. Thanks to the unique integration of smart electronic devices and wearable technologies, we create new demand both from patients already using insulin pens and those not doing so because of reliability issues. Also, around their caregivers, not involved today in business, creating an uncontested market space. In the current market there are smart insulin pen devices, although several reasons make INSULCLOCK unique: 1. It automatically records all critical information related to insulin in-taking for diabetes treatment, without interfering activities of daily living. 2. It stores data taking full advantage of possibilities offered by the Cloud and mobile technologies, assuring security, assistance and privacy. 3. It is universal and reusable. During Phase 1, further business opportunities have been detected, with pharmaceutical and health insurance companies, and relevant leads have been open. Additionally, market barriers and dynamics are fully understood now, allowing us for the definition of the work plan proposed in this Phase 2 application, which will last 15 months with a total budget of 1.48M€. Finally, we created the team, alliances and resources for international high growth. Now is our moment.

 Deliverables

List of deliverables.
Report on technology scouting v1.0 Documents, reports 2019-05-31 10:46:16
Software for health insurance companies Other 2019-05-31 10:46:19
High impact scientific publication around Telemedicine system and impact on health services Documents, reports 2019-05-31 10:46:21
Software for pharmaceutical companies Other 2019-05-31 10:46:18
Tested and validated Telemedicine system Other 2019-05-31 10:46:22
High impact scientific publication on clinical demonstrator of Insulclock Documents, reports 2019-05-31 10:46:21
Report on technology scouting v2.0 Documents, reports 2019-05-31 10:46:26
Family of patents around Insulclock® Other 2019-05-31 10:46:28
Industrial prototypes for trials and demonstrators Demonstrators, pilots, prototypes 2019-05-30 19:01:56

Take a look to the deliverables list in detail:  detailed list of INSULCLOCK deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INSULCLOCK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "INSULCLOCK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ClearRing (2018)

An innovative, minimally invasive medical device used for treatment of Benign Prostatic Hyperplasia symptoms.

Read More